Medication comparison
Mounjaro vs Saxenda
Mounjaro and Saxenda are both prescription medications (GIP/GLP-1 dual receptor agonist vs GLP-1 receptor agonist (daily injection)) used for Type 2 diabetes and Chronic weight management (adults + adolescents 12+). The table below compares FDA-approved indications, dosing, weight-loss outcomes, side effects, contraindications, and current pricing — all sourced from the manufacturer prescribing information.
This is general drug information, not medical advice. Talk to a licensed clinician before starting, stopping, or switching medication.
Drug A
Mounjaro
tirzepatide
GIP/GLP-1 dual receptor agonist
Eli Lilly
See full overviewDrug B
Saxenda
liraglutide
GLP-1 receptor agonist (daily injection)
Novo Nordisk
See full overview| Property | Mounjaro | Saxenda |
|---|---|---|
| Generic name | tirzepatide | liraglutide |
| Drug class | GIP/GLP-1 dual receptor agonist | GLP-1 receptor agonist (daily injection) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Approved indications | Type 2 diabetes | Chronic weight management (adults + adolescents 12+) |
| Brand names | Mounjaro | Saxenda |
| Typical dosing | Titrate to 15 mg (weekly SC injection) | — |
| Top side effects | Nausea (29.6%), Diarrhea (23%), Vomiting (12.6%) | — |
| Contraindications | — | — |
| Boxed warning | Yes | No |
| Pregnancy | C — Discontinue at least 1 month before a planned pregnancy. | — |
| Storage | Refrigerate before first use. After first use, room temperature up to 21 days. | — |
| Avg monthly cost | $1023.04 | $1349.00 |
FDA boxed warning
Mounjaro: Risk of thyroid C-cell tumors. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Frequently asked
What is the difference between Mounjaro and Saxenda?
Mounjaro is tirzepatide (GIP/GLP-1 dual receptor agonist) and Saxenda is liraglutide (GLP-1 receptor agonist (daily injection)). They have different active ingredients and slightly different side-effect profiles.
Is Mounjaro or Saxenda more effective for weight loss?
Head-to-head trial data favors tirzepatide-based medications (Mounjaro, Zepbound) over semaglutide-based medications (Ozempic, Wegovy) in average percent weight loss. See each drug's clinical-trials section for SURMOUNT and STEP trial data.
Can I switch between Mounjaro and Saxenda?
Switching between GLP-1 medications requires re-titration when crossing active ingredients (semaglutide ↔ tirzepatide). Always coordinate with your prescriber before switching.
More medication context
Tools and guides that pair with this comparison.
Overview
Mounjaro full overview
tirzepatide mechanism, dosing, side effects, and pricing.
ReadOverview
Saxenda full overview
liraglutide mechanism, dosing, side effects, and pricing.
ReadLive data
GLP-1 shortage tracker
Real-time FDA shortage status by drug and dose.
ReadFree tool
Are you a candidate?
FDA-criteria decision tree, flags contraindications.
ReadFree tool
Prior auth letter generator
Payer-ready PA letter your prescriber can sign.
ReadLive data
12-month price trends
How telehealth provider pricing has moved over the past year.
Read
Common questions readers ask
- Can you drink alcohol on Wegovy?
- No hard contraindication, but alcohol tolerance often drops sharply on GLP-1. Many patients also report reduced desire for alcohol — likely a secondary effect of GLP-1 on the brain reward system. Full evidence-graded answer
- Does GLP-1 affect oral birth control?
- Tirzepatide (Mounjaro, Zepbound) has documented reduced absorption of oral contraceptives during the first 4 weeks of each dose increase. Use backup contraception for ~4 weeks after starting + after each step-up. Semaglutide has no documented effect. Full evidence-graded answer
- Can I take GLP-1 while pregnant?
- No. All FDA-approved GLP-1s carry a pregnancy contraindication. Stop GLP-1 at least 2 months before planned conception due to its long half-life. Full evidence-graded answer
- Is it safe to take GLP-1 long-term?
- Liraglutide has 15+ years of post-marketing data (Victoza approved 2010). Semaglutide has 8+ years (Ozempic approved 2017). No new class-wide safety signals have emerged in extended follow-up. Chronic use is the FDA-approved indication for both T2D and obesity. Full evidence-graded answer
- Do I need to exercise on Wegovy?
- Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable. Full evidence-graded answer
Affiliate disclosure: we earn commissions when readers sign up through our links. Editorial ranking is independent.